The contribution of Neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background Neurocognitive late effects after childhood acute lymphoblastic leukemia (ALL) are well-documented, but their impact on quality of life (QOL) is not well understood. In this multi-site study, we examined the relative influence of neurocognitive functioning, steroid randomization (prednisone vs. dexamethasone), and demographic characteristics on QOL in first-remission survivors of childhood ALL. Methods Participants included 263 ALL survivors (ages 7-17 years at the time of evaluation; mean age at diagnosis 3.9 years) who were treated on similar legacy Children's Cancer Group chemotherapy protocols and did not receive cranial radiation. Children completed detailed neuropsychological performance tests. The Pediatric QOL Inventory was completed by children and their parents. Participants were a mean of 9 years from diagnosis at the time of assessment (with a range of 4 to 13 years). Results Children and their parents reported lower mean child psychosocial QOL than healthy population norms (p<0.05), but were not in the impaired range. Physical QOL was similar to population norms. Though neurocognitive difficulties were predominantly mild for the sample as a whole, neurocognitive deficits, specifically problems in verbal cognitive abilities and visual-motor integration skills, were significantly associated with poor physical (p<0.01) and Psychosocial QOL (p<0.01). QOL was not associated with previous steroid randomization. Conclusions ALL survivors with neurocognitive deficits are at risk for poor QOL, with broad implications for their physical, social, and school functioning.

Original languageEnglish (US)
Pages (from-to)692-699
Number of pages8
JournalPsycho-Oncology
Volume23
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Quality of Life
Survivors
Random Allocation
Antineoplastic Combined Chemotherapy Protocols
Parents
Steroids
Motor Skills
Aptitude
Neuropsychological Tests
Prednisone
Dexamethasone
Population
Demography
Radiation
Pediatrics
Equipment and Supplies

Keywords

  • cognitive function
  • neuropsychology
  • oncology
  • pediatric cancer
  • quality of life

Cite this

The contribution of Neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia. / Kunin-Batson, Alicia S; Kadan-Lottick, Nina; Neglia, Joseph P.

In: Psycho-Oncology, Vol. 23, No. 6, 01.01.2014, p. 692-699.

Research output: Contribution to journalArticle

@article{326d6763f05a4d62bce4225471697717,
title = "The contribution of Neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia",
abstract = "Background Neurocognitive late effects after childhood acute lymphoblastic leukemia (ALL) are well-documented, but their impact on quality of life (QOL) is not well understood. In this multi-site study, we examined the relative influence of neurocognitive functioning, steroid randomization (prednisone vs. dexamethasone), and demographic characteristics on QOL in first-remission survivors of childhood ALL. Methods Participants included 263 ALL survivors (ages 7-17 years at the time of evaluation; mean age at diagnosis 3.9 years) who were treated on similar legacy Children's Cancer Group chemotherapy protocols and did not receive cranial radiation. Children completed detailed neuropsychological performance tests. The Pediatric QOL Inventory was completed by children and their parents. Participants were a mean of 9 years from diagnosis at the time of assessment (with a range of 4 to 13 years). Results Children and their parents reported lower mean child psychosocial QOL than healthy population norms (p<0.05), but were not in the impaired range. Physical QOL was similar to population norms. Though neurocognitive difficulties were predominantly mild for the sample as a whole, neurocognitive deficits, specifically problems in verbal cognitive abilities and visual-motor integration skills, were significantly associated with poor physical (p<0.01) and Psychosocial QOL (p<0.01). QOL was not associated with previous steroid randomization. Conclusions ALL survivors with neurocognitive deficits are at risk for poor QOL, with broad implications for their physical, social, and school functioning.",
keywords = "cognitive function, neuropsychology, oncology, pediatric cancer, quality of life",
author = "Kunin-Batson, {Alicia S} and Nina Kadan-Lottick and Neglia, {Joseph P}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/pon.3470",
language = "English (US)",
volume = "23",
pages = "692--699",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - The contribution of Neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia

AU - Kunin-Batson, Alicia S

AU - Kadan-Lottick, Nina

AU - Neglia, Joseph P

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background Neurocognitive late effects after childhood acute lymphoblastic leukemia (ALL) are well-documented, but their impact on quality of life (QOL) is not well understood. In this multi-site study, we examined the relative influence of neurocognitive functioning, steroid randomization (prednisone vs. dexamethasone), and demographic characteristics on QOL in first-remission survivors of childhood ALL. Methods Participants included 263 ALL survivors (ages 7-17 years at the time of evaluation; mean age at diagnosis 3.9 years) who were treated on similar legacy Children's Cancer Group chemotherapy protocols and did not receive cranial radiation. Children completed detailed neuropsychological performance tests. The Pediatric QOL Inventory was completed by children and their parents. Participants were a mean of 9 years from diagnosis at the time of assessment (with a range of 4 to 13 years). Results Children and their parents reported lower mean child psychosocial QOL than healthy population norms (p<0.05), but were not in the impaired range. Physical QOL was similar to population norms. Though neurocognitive difficulties were predominantly mild for the sample as a whole, neurocognitive deficits, specifically problems in verbal cognitive abilities and visual-motor integration skills, were significantly associated with poor physical (p<0.01) and Psychosocial QOL (p<0.01). QOL was not associated with previous steroid randomization. Conclusions ALL survivors with neurocognitive deficits are at risk for poor QOL, with broad implications for their physical, social, and school functioning.

AB - Background Neurocognitive late effects after childhood acute lymphoblastic leukemia (ALL) are well-documented, but their impact on quality of life (QOL) is not well understood. In this multi-site study, we examined the relative influence of neurocognitive functioning, steroid randomization (prednisone vs. dexamethasone), and demographic characteristics on QOL in first-remission survivors of childhood ALL. Methods Participants included 263 ALL survivors (ages 7-17 years at the time of evaluation; mean age at diagnosis 3.9 years) who were treated on similar legacy Children's Cancer Group chemotherapy protocols and did not receive cranial radiation. Children completed detailed neuropsychological performance tests. The Pediatric QOL Inventory was completed by children and their parents. Participants were a mean of 9 years from diagnosis at the time of assessment (with a range of 4 to 13 years). Results Children and their parents reported lower mean child psychosocial QOL than healthy population norms (p<0.05), but were not in the impaired range. Physical QOL was similar to population norms. Though neurocognitive difficulties were predominantly mild for the sample as a whole, neurocognitive deficits, specifically problems in verbal cognitive abilities and visual-motor integration skills, were significantly associated with poor physical (p<0.01) and Psychosocial QOL (p<0.01). QOL was not associated with previous steroid randomization. Conclusions ALL survivors with neurocognitive deficits are at risk for poor QOL, with broad implications for their physical, social, and school functioning.

KW - cognitive function

KW - neuropsychology

KW - oncology

KW - pediatric cancer

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84902077784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902077784&partnerID=8YFLogxK

U2 - 10.1002/pon.3470

DO - 10.1002/pon.3470

M3 - Article

C2 - 24497266

AN - SCOPUS:84902077784

VL - 23

SP - 692

EP - 699

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 6

ER -